The interim access policy, requested by the American Academy of Peptide Medicine, now awaits OMB review. The group's chair says it would help squeeze out gray-market sellers.
Recap by typeshit. Full story at Independent Journal Review.
Judge Raphael Leite Guedes in Maranhão found tirzepatide counts as a home-use drug under Law 9,656/98, even when a clinic gives the shots.
Inc. reports that some Georgia clinics are still marketing an unapproved Lilly weight loss drug even as the company moves against its sale.
After advisers backed adding BPC-157, TB-500, KPV and others to the 503A bulks list, pharmacists are waiting on the FDA's final decision.
Supporters of MAHA are arguing for fewer barriers to experimental peptides, framing it as personal freedom to choose what to take. Thin details in the post.
The Daily Caller reports the policy is slotted for sign-off at the White House, following FDA action on six peptide drugs.
Sinai Health says early research hints semaglutide-type drugs may ease inflammation apart from weight loss, and Ren is working out the mechanism.
Loading…